Lab monitoring is not required for psoriasis patients treated with deucravacitinib (Sotyktu, BMS), according to a new expert consensus panel. In this video, study author Milaan Shah, MD, a Dermatology Resident at the Medical University of South Carolina in Charleston, SC, reviews the findings , which are published in the February 2025 issue of the Journal of Drugs in Dermatology.
Dr. Shah and colleagues conducted a literature search for original research articles on the efficacy and safety of deucravacitinib. Fourteen articles were selected for review by 10 dermatologists. The panel crafted six consensus statements regarding efficacy and safety and recommended laboratory monitoring for deucravacitinib.
